TLDR
- ARK Invest divested 46,015 Twist Bioscience shares valued at $5.8 million via its ARKK ETF
- Additional disposals included positions in 10X Genomics, Bullish, Tempus AI, and Alphabet
- Meta Platforms received $27.9 million investment from two ARK funds on September 9
- With Rocket Lab down nearly 60% from peak levels, ARK acquired approximately $45 million in shares from August 31 through September 8
- Intellia Therapeutics sees continued ARK accumulation with nearly 115,000 shares purchased
On Friday, September 11, 2026, Cathie Wood’s ARK Invest executed a series of strategic portfolio adjustments, trimming multiple holdings while significantly increasing exposure to artificial intelligence platforms and space-economy enterprises.
The most substantial divestment involved 46,015 Twist Bioscience shares through the ARKK ETF, representing approximately $5.8 million in value. This marks the continuation of a multi-week reduction in ARK’s Twist Bioscience holdings.
Additional exits included 60,556 shares of 10X Genomics valued near $4 million, alongside 121,217 Bullish shares worth roughly $4.1 million. Minor position reductions also affected Tempus AI, GeneDx Holdings, and Alphabet.
Conversely, ARK acquired nearly 115,000 Intellia Therapeutics shares, representing approximately $1.4 million. This purchase extends a consistent pattern of accumulating the gene-editing specialist throughout the previous week.
ARK Makes Substantial Meta Investment
A pair of ARK funds collectively acquired $27.9 million in Meta Platforms equity on September 9. Meta’s stock currently sits roughly 18% beneath its historical peak.
Meta Platforms, Inc., META
According to ARK’s research analysts, Meta’s ecosystem of 3.6 billion daily active users across its applications represents a formidable competitive moat. The social media giant leverages artificial intelligence to enhance advertisement precision and content curation throughout its platform suite.
The company delivered second-quarter revenue expansion of 28% compared to the prior year. CEO Mark Zuckerberg emphasized that Meta’s advertising segment is experiencing faster growth than any competitor’s disclosed advertising operations when measured in absolute dollar terms.
Meta’s capital expenditure forecast for 2026 ranges between $165 billion and $169 billion. Wood seemingly anticipates these infrastructure investments will yield enhanced free cash flow generation in subsequent periods. The equity currently commands a forward price-to-earnings ratio of 21.
Rocket Lab Receives Major ARK Allocation
Between August 31 and September 8, three separate ARK ETFs accumulated approximately $45 million worth of Rocket Lab equity. The space company’s shares have declined nearly 60% from their record high of $151 achieved earlier in 2026.
Rocket Lab posted 62% year-over-year revenue growth during the second quarter, accompanied by an unprecedented backlog totaling $2.36 billion. New contract bookings worth $437 million materialized since the end of March.
CEO Peter Beck characterized launch service demand as “extreme.” Company leadership highlighted that available launch windows extending beyond 2029 are “extremely limited,” potentially creating pricing power as industry demand accelerates.
The company is also in the process of acquiring Iridium, which maintains a constellation of 66 satellites serving over 2.5 million subscribers. Wood appears to view Rocket Lab as a comprehensive space infrastructure investment thesis.
ARK’s primary ARKK ETF has generated approximately 9% returns during 2026, underperforming broader market indices. However, four additional ARK strategies have delivered superior performance relative to the S&P 500 across the trailing three-year period.
The firm’s latest acquisitions underscore a deliberate emphasis on AI-powered technology platforms and orbital infrastructure as the final quarter of 2026 approaches.
The post Cathie Wood’s ARK Invest Doubles Down on Meta (META) and Rocket Lab in September Moves appeared first on Blockonomi.
Be the first to comment